Is XENE or XERS more undervalued in 2026?

CirclFi compares Xenon Pharmaceuticals Inc. (XENE) and Xeris Biopharma Holdings, Inc. (XERS) using 13 institutional-grade valuation models. XENE has a Quality of Company score of 5.4/10 while XERS scores 8.6/10.

Which is a better buy — XENE or XERS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do XENE and XERS valuations compare?

XENE at $54.73 and XERS at $6.16 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

XENE vs XERS Valuation Comparison 2026 — Intrinsic Value Analysis

XENE

Pharmaceutical Preparations

Xenon Pharmaceuticals Inc.

Quality

5.4

out of 10

Value Trap

LOW

Price

$54.73

Last close

Models

12/13

Active

XERS

Pharmaceutical Preparations

Xeris Biopharma Holdings, Inc.

Quality

8.6

out of 10

Value Trap

LOW

Price

$6.16

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	XENE Fair Value	XENE Upside	XERS Fair Value	XERS Upside
Bayesian DCF	Intrinsic	$19.87	-63.7%	$1.45	-76.5%
Earnings Power Value	Intrinsic	$24.80	-55.1%	$0.13	-97.8%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for XENE vs XERS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

XENE vs XERS — Which Stock Is More Undervalued?

XERS scores higher with a 8.6/10 quality rating vs XENE's 5.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Xenon Pharmaceuticals Inc. (XENE) and Xeris Biopharma Holdings, Inc. (XERS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

XENE currently trades at $54.73 with a QOC of 5.4/10, while XERS trades at $6.16 with a QOC of 8.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).